Unknown

Dataset Information

0

Peptide lipidation stabilizes structure to enhance biological function.


ABSTRACT: Medicines that decrease body weight and restore nutrient tolerance could improve human diabetes and obesity treatment outcomes. We developed lipid-acylated glucagon analogs that are co-agonists for the glucagon and glucagon-like peptide 1 receptors, and stimulate weight loss and plasma glucose lowering in pre-diabetic obese mice. Our studies identified lipid acylation (lipidation) can increase and balance in vitro potencies of select glucagon analogs for the two aforementioned receptors in a lipidation site-dependent manner. A general capacity for lipidation to enhance the secondary structure of glucagon analogs was recognized, and the energetics of this effect quantified. The molecular structure of a lipid-acylated glucagon analog in water was also characterized. These results support that lipidation can modify biological activity through thermodynamically-favorable intramolecular interactions which stabilize structure. This establishes use of lipidation to achieve specific pharmacology and implicates similar endogenous post-translational modifications as physiological tools capable of refining biological action in means previously underappreciated.

SUBMITTER: Ward BP 

PROVIDER: S-EPMC3854995 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7523912 | biostudies-literature
| S-EPMC5985209 | biostudies-literature
| S-EPMC8347091 | biostudies-literature
| S-EPMC7040957 | biostudies-literature
| S-EPMC4364393 | biostudies-literature
| S-EPMC7897624 | biostudies-literature
| S-EPMC2762582 | biostudies-literature
| S-EPMC10945551 | biostudies-literature
| S-EPMC4509441 | biostudies-literature
| S-EPMC4275590 | biostudies-literature